“So, while the natural epidemiological prevalence of disease is only 20% to 30%, we really should aim for studies where we can oversample the females to make sure that that medication truly is doing what it's doing in both males and females,” says Laura Bukavina, MD, MPH, MS.
"The patients who received SBRT were more likely to be Caucasian. We observed that far fewer Black men were treated with SBRT in our cohort," says Michael Stencel, DO.
“We are finding more and more information and evidence to support recommendations to try and reduce the infection rates,” says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.
"For more rural practices, for ureteroscopy, they also received lower reimbursement than urban practices," says Victoria S. Edmonds, MD.
“[This way, I can] educate myself and put myself in their shoes and suggest a treatment or a plan or an evaluation, and then find out what their feedback might be from a collaborative standpoint,” say Robert D. Hoy, MPAS, PA-C.
"Our hope is that if we can improve the experience of their initial treatment for urinary retention, then particularly the patients who actually need to catheterize to maintain their kidney health, they would not be afraid of catheterization," says Jennifer Ann Meddings, MD, MSc.
The key opinion leaders explore various treatment approaches for prostate cancer, including surgery, radiation, and hormone therapy, explaining how biomarker results influence their treatment choices. They also detail the specific criteria they use to select between treatment options based on biomarker testing outcomes.
The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.
This discussion explores the differences in the effects of abiraterone formulations when combined with prednisone or methylprednisolone.
This discussion provides an overview of abiraterone and the key differences between micronized and non-micronized formulations, including considerations for choosing between the two formulations.
“Unlike a lot of the societies within oncology, including ASCO or even NCCN, urology really does not do a good job at recommending mental health to our patients,” says Laura Bukavina, MD, MPH, MSc.
"The patients in these networks that were treated with SBRT certainly lived in areas with increased incomes," says Michael Stencel, DO.
"We have now realized that in some patients with a low number of metastatic sites, providing systemic treatment and providing some site-targeted treatment will provide lasting benefit or at least a temporary benefit that will help ameliorate the need for the systemic treatments or very intense systemic treatments," says Armine K. Smith, MD.
"Based on our work, it does show that ileal ureter replacement can be an effective long-term option for patients with long-segment ureteral stricture disease," says Ziho Lee, MD.
“While the medications might be covered, while the surgical treatment might be covered, we all know that mental health and dental care are one of those things where people have large copays, long delays to care, and it is very clear to see that from our study,” says Laura Bukavina, MD, MPH, MSc.
Experts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
Stephen Freedland, MD, discusses the role of GnRH agonists and antagonists on improving cardiovascular outcomes in patients with prostate cancer.
Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.
Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.
"A lot of studies were done in a way that weren't randomized," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.
"We hypothesize that when we treat female sexual dysfunction, we can ultimately improve the dynamics between the couple, and therefore improve the male partner satisfaction with his IPP," says Thairo Pereira, MD.
"We're actually standardizing how to clean the catheter, because the system tells you exactly [how]," says Ana Lidia Flores-Mireles, PhD.
“Sometimes there's some difficulties with continuity of care, because I'm not the sole provider for that patient,” says Robert D. Hoy, MPAS, PA-C.
"The number of treatment centers that are offering stereotactic body radiation [grew] over the course of the study," says Michael Stencel, DO.
Dean Elterman, MD, covers minimally invasive surgical therapies (MIST) for BPH, including laser therapy, prostatic urethral lift, and others, their impact on BPH management, AUA guidelines, patient selection, and the role of patient preference in choosing between MIST, medication, and surgery.
"I actually worked with several different urologists while we were developing this," says Jennifer Ann Meddings, MD.
Dean Elterman, MD, discusses historical treatment options for BPH, including both pharmacotherapy and surgical methods, their effectiveness, and how to identify patients who would benefit from treatment based on quality of life, risk of lower urinary tract symptoms, and other factors. It also addresses challenges such as long-term complications and patient adherence.
"We ended up with 3091 participants overall, and 3 trends came out that were significant," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.
Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.
Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.
